{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:08:17Z","timestamp":1788120497853,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd011600.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000}}],"reference-count":111,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011600.pub3","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T12:43:00Z","timestamp":1701866580000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2024","author":[{"given":"Wouter H","family":"van Geffen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases; Medical Center Leeuwarden; Leeuwarden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Tan","sequence":"additional","affiliation":[{"name":"Allergy and Lung Health Unit, Melbourne School of Population and Global Health; University of Melbourne; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia AE","family":"Walters","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Tasmania; Hobart Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Haydn","family":"Walters","sequence":"additional","affiliation":[{"name":"NHMRC Centre of Research Excellence for Chronic Respiratory Disease; School of Medicine, University of Tasmania; Hobart Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD011600.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","article-title":"Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"issue":"18","key":"10.1002\/14651858.CD011600.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011600.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1183\/13993003.02165-2015","article-title":"A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol","volume":"48","author":"Pascoe","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"10125","key":"10.1002\/14651858.CD011600.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.rmed.2019.08.010","article-title":"A phase III study of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler 320\/18\/9.6mug and 160\/18\/9.6mug using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol","volume":"158","author":"Rabe","year":"2019","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.rmed.2019.08.010","article-title":"A phase III study of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler 320\/18\/9.6mug and 160\/18\/9.6mug using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol","volume":"158","author":"Rabe","year":"2019","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.rmed.2019.08.010","article-title":"A phase III study of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler 320\/18\/9.6mug and 160\/18\/9.6mug using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol","volume":"158","author":"Rabe","year":"2019","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011600.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Single inhaler triple therapy for COPD Drug and Therapeutics Bulletin 2017 55 12 138 141","DOI":"10.1136\/dtb.2017.12.0562"},{"issue":"3","key":"10.1002\/14651858.CD011600.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14656566.2017.1419186","article-title":"Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction","volume":"19","author":"Antohe","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0014|cit14","first-page":"A5782","article-title":"Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combination in patients with moderate to severe COPD, stratified by inhaled corticosteroid use","volume":"191","author":"Bateman","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/COPD.S122354","article-title":"Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD","volume":"12","author":"Bishwakarma","year":"2017","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"6","key":"10.1002\/14651858.CD011600.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ejcts.2010.09.025","article-title":"Short-term effects of inhalative tiotropium\/formoterol\/budesonide versus tiotropium\/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomised trial","volume":"39","author":"B\u00f6l\u00fckbas","year":"2011","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0017|cit17","first-page":"A1009","article-title":"Withdrawal of inhaled corticosteroids from COPD patients inhaling long-term triple therapy: the SUNSET study","volume":"197","author":"Chapman","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011600.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-term triple therapy de-escalation to indacaterol\/ glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011600.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"A1722","DOI":"10.1016\/j.chest.2020.08.1526","article-title":"Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the impact trial","volume":"158","author":"Dransfield","year":"2020","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0020|cit20","unstructured":"Single inhaler triple therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) \u2013 COPD https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004369-29\/results 2018"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0021|cit21","unstructured":"Phase 3b study to evaluate the effects of budesonide\/glycopyrronium\/formoterol fuumarate and glycopyrronium\/formoterol fumarate on specific image based airway volumes and resistance in subjects with chronic obstructive pulmonary disease (COPD) https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02068001\/full 2018"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0022|cit22","unstructured":"Study to the effects of using \"triple therapy\" on the health status of COPD patients with characteristics of asthma https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2019-003351-11 2019"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011600.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"A1656","DOI":"10.1016\/j.chest.2020.08.1490","article-title":"Benefits of budesonide-containing therapies on reducing lung function decline in patients with COPD in the ETHOS study","volume":"158","author":"Ferguson","year":"2020","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011600.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/j.jval.2018.04.1596","article-title":"A cost-effectiveness analysis of a first-in-class, triple fixed dose combination therapy against LABA\/LAMA therapy in moderate-severe COPD","volume":"21","author":"Gosden","year":"2018","journal-title":"Value in Health"},{"issue":"9","key":"10.1002\/14651858.CD011600.pub3-BIB0025|cit25","first-page":"A3339","article-title":"The IMPACT trial: single inhaler triple therapy fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol and umeclidinium\/vilanterol in patients with COPD: analysis according to smoking status","volume":"199","author":"Halpin","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011600.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1901921","DOI":"10.1183\/13993003.01921-2019","article-title":"The effect of exacerbation history on outcomes in the IMPACT trial","volume":"55","author":"Halpin","year":"2020","journal-title":"European Respiratory Journal"},{"issue":"9","key":"10.1002\/14651858.CD011600.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1164\/rccm.201912-2478OC","article-title":"The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial","volume":"202","author":"Han","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0028|cit28","unstructured":"Hara K Kurashima K Tokunaga D Ueno M Aoyagi K Isobe Z Single blind comparison of tiotropium and salmeterol plus fluticasone propionate of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract] American Thoracic Society International Conference; 2007 May 18-23; San Francisco San Francisco, California, USA 2007 Poster #A1"},{"issue":"suppl 64","key":"10.1002\/14651858.CD011600.pub3-BIB0029|cit29","first-page":"3276","article-title":"Triple therapy with fluticasone furoate\/umeclidinium\/vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids\/dual bronchodilation in patients with chronic obstructive pulmonary disease","volume":"56","author":"Harada","year":"2020","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"S01","DOI":"10.1055\/s-0037-1619366","article-title":"TriOptimize: a prospective non-interventional trial to document potential optimization of health related quality of life in COPD patients prescribed a fixed vs. free LAMA\/LABA\/ICS triple therapy","volume":"72","author":"Hovelmann","year":"2018","journal-title":"Pneumologie"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.2147\/COPD.S220861","article-title":"Long-term safety and efficacy of budesonide\/ glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD","volume":"14","author":"Ichinose","year":"2019","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011600.pub3-BIB0032|cit32","first-page":"S29","article-title":"A comparative study on inhaled corticosteroids versus placebo in management of chronic obstructive pulmonary disease","volume":"30","author":"James","year":"2013","journal-title":"Lung India"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2147\/COPD.S226601","article-title":"The IMPACT study \u2013 single inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI and UMEC\/VI in patients with COPD: efficacy and safety in a Japanese population","volume":"14","author":"Kato","year":"2019","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0034|cit34","first-page":"A3319","article-title":"Bone mineral density and ocular safety after 52 weeks' treatment with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler (BGF MDI) using co-suspension delivery technology in COPD","volume":"199","author":"Kerwin","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011600.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.22159\/ijpps.2018v10i4.24529","article-title":"A comparative evaluation of the efficacy of triple drug therapy with dual drug therapy in COPD patients","volume":"10","author":"Khan","year":"2018","journal-title":"International Journal of Pharmacy and Pharmaceutical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD011600.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/CPM.0000000000000275","article-title":"IMPACT Trial: triple versus dual therapy for COPD results in decreased rate of exacerbations","volume":"25","author":"Krishnan","year":"2018","journal-title":"Clinical Pulmonary Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011600.pub3-BIB0037|cit37","first-page":"e236","article-title":"Triple versus dual therapy in COPD: a meta-analysis","volume":"32","author":"Lipari","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0038|cit38","first-page":"A3334","article-title":"The IMPACT trial: single inhaler triple therapy fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol and umeclidinium\/vilanterol in patients with COPD: results on cardiovascular safety","volume":"199","author":"Lipson","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"PA2482","DOI":"10.1183\/13993003.congress-2019.PA2482","article-title":"The IMPACT Trial: single inhaler triple therapy vs dual therapies: efficacy across multiple COPD endpoints over time","volume":"54","author":"Lipson","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD011600.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"63A","DOI":"10.1378\/chest.1994339","article-title":"Exacerbation risk is not worse when ICS are withdrawn in a stepwise manner in severe to very severe COPD patients receiving LAMA+LABA: The WISDOM study","volume":"146","author":"Magnussen","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD011600.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"76A","DOI":"10.1378\/chest.1994402","article-title":"The impact of stepwise withdrawal of ICS on FEV1, mMRC, and SQRQ in severe to very severe COPD patients treated with LAMA+LABA: The WISDOM study","volume":"146","author":"Magnussen","year":"2014","journal-title":"Chest"},{"issue":"14","key":"10.1002\/14651858.CD011600.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0043|cit43","first-page":"A2241","article-title":"All-cause mortality by subgroup in patients with chronic obstructive pulmonary disease: post hoc analysis of the impact trial","volume":"203","author":"Mammen","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011600.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for COPD: a randomized, double-blind, multi-center parallel-group study","volume":"203","author":"Martinez","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0045|cit45","first-page":"A4770","article-title":"Clinical usefulness of once-daily triple therapy, ciclesonide and tiotropium bromide\/olodaterol combination inhaler for COPD patients","volume":"197","author":"Masayuki","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0046|cit46","first-page":"A3029","article-title":"Population pharmacokinetic analysis of single inhaler triple therapy (ICS\/LAMA\/LABA) versus dual therapy (LAMA\/LABA AND ICS\/LABA) in patients with symptomatic COPD: combined results from three phase iii trials","volume":"197","author":"Mehta","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD011600.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.drudis.2016.07.009","article-title":"Triple inhaled therapy for chronic obstructive pulmonary disease","volume":"21","author":"Montuschi","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0048|cit48","unstructured":"Efficacy of fixed combination of beclometasone + formoterol + glycopyrrolate in chronic obstructive pulmonary disease clinicaltrials.gov\/ct2\/show\/NCT01911364"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0049|cit49","unstructured":"Comparative study of fluticasone furoate(FF)\/umeclidinium bromide (UMEC)\/ vilanterol (VI) closed therapy versus FF\/VI plus UMEC open therapy in subjects with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT02729051"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0050|cit50","unstructured":"A study comparing the closed triple therapy, open triple therapy and a dual therapy for effect on lung function in subjects with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT02731846"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0051|cit51","unstructured":"A randomized study, comparing fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) single inhaler triple therapy, versus multiple inhaler therapy (budesonide\/formoterol plus tiotropium) in subjects with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT03478683"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0052|cit52","unstructured":"A phase III study comparing efficacy, safety and tolerability of the fixed dose triple combination CHF 5993 with the fixed dose dual combination CHF 1535 in subjects With COPD https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320342"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0053|cit53","unstructured":"The effects of inhaled budesonide-formoterol-glycopyrronium in moderate-to-severe COPD https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04675463"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0054|cit54","unstructured":"A study to evaluate the safety and efficacy of fluticasone furoate (FF)\/umeclidinium(UMEC)\/vilanterol (VI) in participants with chronic obstructive pulmonary disease (COPD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04923347"},{"issue":"15","key":"10.1002\/14651858.CD011600.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2217\/cer-2019-0101","article-title":"Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease","volume":"8","author":"Palli","year":"2019","journal-title":"Journal of Comparative Effectiveness Research"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0056|cit56","first-page":"A7725","article-title":"Reduction in fatal events with ICS-containing medications: results of safety pooled analysis from the TRILOGY, TRINITY and TRIBUTE studies","volume":"197","author":"Scuri","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"10048","key":"10.1002\/14651858.CD011600.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD011600.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14656566.2018.1498841","article-title":"Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease","volume":"19","author":"Singh","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0059|cit59","first-page":"A1591","article-title":"COPD assessment test (CAT) score is associated with risk of future exacerbation: an analysis from the IMPACT trial","volume":"199","author":"Stiegler","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011600.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"A1782","DOI":"10.1016\/j.chest.2020.08.1555","article-title":"Functional respiratory imaging assessment of budesonide\/glycopyrrolate\/formoterol fumarate and glycopyrrolate\/formoterol fumarate metered dose inhalers in patients with COPD","volume":"158","author":"den Berge","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD011600.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12931-021-01772-2","article-title":"Functional respiratory imaging assessment of budesonide\/glycopyrrolate\/formoterol fumarate and glycopyrrolate\/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids","volume":"22","author":"den Berge","year":"2021","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000341382","article-title":"Pathophysiology of the small airways in chronic obstructive pulmonary disease","volume":"84","author":"Baraldo","year":"2012","journal-title":"Respiration"},{"issue":"3","key":"10.1002\/14651858.CD011600.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/17476348.2014.910457","article-title":"Recent advances in COPD disease management with fixed-dose long-acting combination therapies","volume":"8","author":"Bateman","year":"2014","journal-title":"Expert Review of Respiratory Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/COPD.S291030","article-title":"Comparison of dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium in patients with COPD: The TRI-D randomized controlled trial","volume":"16","author":"Beeh","year":"2021","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"9589","key":"10.1002\/14651858.CD011600.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0066|cit66","unstructured":"Yang IA Brown JL George J Jenkins S McDonald CF McDonald V Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease 2019 Version 2.58, June 2019 copdx.org.au\/wp-content\/uploads\/2019\/09\/COPDX-V2-58-June-2019-FINAL2.pdf"},{"issue":"4","key":"10.1002\/14651858.CD011600.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/13543784.2014.876409","article-title":"Considerations for new dual-acting bronchodilator treatments for chronic obstructive pulmonary disease","volume":"23","author":"Miguel-D\u00edez","year":"2014","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"10","key":"10.1002\/14651858.CD011600.pub3-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008989.pub3","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","author":"Farne","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011600.pub3-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3109\/15412555.2011.560131","article-title":"Triple therapy for the management of COPD: a review","volume":"8","author":"Gaebel","year":"2011","journal-title":"COPD"},{"issue":"1","key":"10.1002\/14651858.CD011600.pub3-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010139.pub2","article-title":"Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease","author":"Geake","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0071|cit71","unstructured":"Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (2023 report) https:\/\/goldcopd.org\/wp-content\/uploads\/2023\/03\/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf 2023"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/COPD.S34186","article-title":"Exacerbation frequency and course of COPD","volume":"7","author":"Halpin","year":"2012","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"55","key":"10.1002\/14651858.CD011600.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1901874","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"14","author":"Hartl","year":"2020","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0074|cit74","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0075|cit75","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"9","key":"10.1002\/14651858.CD011600.pub3-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009039.pub2","article-title":"The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Karner","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011600.pub3-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008989.pub2","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","author":"Karner","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD011600.pub3-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010177.pub2","article-title":"Long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Kew","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011600.pub3-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010844.pub2","article-title":"Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis","author":"Kew","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011600.pub3-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010115.pub2","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","author":"Kew","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2147\/COPD.S200846","article-title":"The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Lai","year":"2019","journal-title":"International Journal of COPD"},{"issue":"4","key":"10.1002\/14651858.CD011600.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.rmed.2009.10.024","article-title":"Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype","volume":"104","author":"Lee","year":"2009","journal-title":"Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011600.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pupt.2004.10.005","article-title":"Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept","volume":"18","author":"Leuppi","year":"2005","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD011600.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.arbr.2011.01.003","article-title":"Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity","volume":"47","author":"Miravitlles","year":"2011","journal-title":"Archivos de Bronconeumologia"},{"issue":"12","key":"10.1002\/14651858.CD011600.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2174\/0929867311320120002","article-title":"Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD","volume":"20","author":"Montuschi","year":"2013","journal-title":"Current Medicinal Chemistry"},{"issue":"10","key":"10.1002\/14651858.CD011600.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1021\/jm5013227","article-title":"Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends","volume":"58","author":"Montuschi","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1002\/14651858.CD011600.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.drudis.2016.07.009","article-title":"Triple inhaled therapy for chronic obstructive pulmonary disease","volume":"21","author":"Montuschi","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0088|cit88","unstructured":"National Institute for Health and Care Excellence Chronic obstructive pulmonary disease in over 16s: diagnosis and management NICE guideline [NG115] www.nice.org.uk\/guidance\/ng115"},{"issue":"9","key":"10.1002\/14651858.CD011600.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0090|cit90","unstructured":"PlotDigitizer Porbital 2022"},{"issue":"2","key":"10.1002\/14651858.CD011600.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1513\/pats.2306026","article-title":"Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease","volume":"1","author":"Rennard","year":"2004","journal-title":"Proceedings of the American Thoracic Society"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0092|cit92","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2020"},{"issue":"2","key":"10.1002\/14651858.CD011600.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1378\/chest.13-2807","article-title":"Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review","volume":"146","author":"Rodrigo","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/jrsm.1259","article-title":"Methods for including information from multi-arm trials in pairwise meta-analysis","volume":"8","author":"R\u00fccker","year":"2017","journal-title":"Research Synthesis Methods"},{"issue":"5","key":"10.1002\/14651858.CD011600.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD011600.pub3-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007033.pub2","article-title":"Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Spencer","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011600.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4104\/pcrj.2011.00102","article-title":"Beyond lung function in COPD management: effectiveness of LABA\/LAMA combination therapy on patient-centred outcomes","volume":"21","author":"Molen","year":"2012","journal-title":"Primary Care Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD011600.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.200206-512OC","article-title":"Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study","volume":"166","author":"Valk","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011600.pub3-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011826.pub2","article-title":"Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD","author":"Geffen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0100|cit100","first-page":"1269\u201377","article-title":"Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease","volume":"13","author":"Geffen","year":"2018","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"4","key":"10.1002\/14651858.CD011600.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-2600(18)30431-4","article-title":"Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis","volume":"7","author":"Geffen","year":"2019","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"106064","DOI":"10.1016\/j.rmed.2020.106064","article-title":"Long-acting dual bronchodilator therapy (indacaterol\/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol\/ipratropium) in chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled trial","volume":"171","author":"Geffen","year":"2020","journal-title":"Respiratory Medicine"},{"issue":"13","key":"10.1002\/14651858.CD011600.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa1105482","article-title":"Changes in forced expiratory volume in 1 second over time in COPD","volume":"365","author":"Vestbo","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011600.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1440-1843.2005.00718.x","article-title":"Outcomes and health-related quality of life following hospitalisation for an acute exacerbation of COPD","volume":"10","author":"Wang","year":"2005","journal-title":"Respirology"},{"issue":"5","key":"10.1002\/14651858.CD011600.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1741-7015-11-181","article-title":"Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease","volume":"11","author":"Wedzicha","year":"2013","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD011600.pub3-BIB0107|cit107","unstructured":"World Health Organization WHO Global Report: mortality attributable to tobacco whqlibdoc.who.int\/publications\/2012\/9789241564434_eng.pdf"},{"issue":"7","key":"10.1002\/14651858.CD011600.pub3-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002991.pub3","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011600.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/crj.13026","article-title":"Triple versus dual inhaler therapy in moderate-to-severe COPD: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Zayed","year":"2018","journal-title":"Clinical Respiratory Journal"},{"issue":"8176","key":"10.1002\/14651858.CD011600.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"k4388","DOI":"10.1136\/bmj.k4388","article-title":"Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis","volume":"363","author":"Zheng","year":"2018","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD011600.pub3-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011600.pub2","article-title":"Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease","author":"Tan","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:48:00Z","timestamp":1760608080000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011600.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":111,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011600.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}